Negative-pressure wound therapy

MIMEDX Announces Launch of AXIOFILL™

Retrieved on: 
Tuesday, September 20, 2022

MARIETTA, Ga., Sept. 20, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced the launch of AXIOFILL™, an Extracellular Matrix (ECM) Particulate product derived from human placental tissue.

Key Points: 
  • MARIETTA, Ga., Sept. 20, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (MIMEDX or the Company), a transformational placental biologics company, today announced the launch of AXIOFILL, an Extracellular Matrix (ECM) Particulate product derived from human placental tissue.
  • AXIOFILL is the first and only human placental-derived particulate product available for Surgical Recovery procedures.
  • AXIOFILL provides a cost-effective human collagen scaffold that is conducive for use in large, complex wounds and those of irregular geometries.
  • The launch of AXIOFILL is particularly significant for MIMEDX, said Rohit Kashyap, Ph.D., MIMEDX President, Wound Care & Surgical.

3M upgrades make negative pressure wound therapy with instillation easier for clinicians to initiate

Retrieved on: 
Thursday, August 4, 2022

These new offerings help simplify the care delivery processes for clinicians using Veraflo Therapy (negative pressure wound therapy with instillation) and help make dressing changes easier, faster, and less painful for their patients as compared to previous Veraflo Therapy dressings.

Key Points: 
  • These new offerings help simplify the care delivery processes for clinicians using Veraflo Therapy (negative pressure wound therapy with instillation) and help make dressing changes easier, faster, and less painful for their patients as compared to previous Veraflo Therapy dressings.
  • A recent publication by Gabriel et al Effects of Negative-Pressure Wound Therapy with Instillation versus Standard of Care in Multiple Wound Types: Systematic Literature Review and Meta-Analysis, shows that Veraflo Therapy demonstrated significant clinical advantages and economic savings versus other advanced wound therapies, including traditional negative pressure wound therapy (NPWT).
  • "We continue to find ways to innovate to meet their unique wound care needs and address the changing nature of wound care.
  • The device's newly upgraded software, which includes the 3M Smart Instill Feature for use with Veraflo Therapy, automates therapy initiation and makes it easier for clinicians to initiate therapy.

Global Negative Pressure Wound Therapy (NPWT) Market Report 2022: Market to Reach $3.1 Billion by 2026 - Technological Advancements and New Product Launches Crucial to Sustain Future Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 17, 2022

The "Negative Pressure Wound Therapy (NPWT) - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Negative Pressure Wound Therapy (NPWT) - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Negative pressure wound therapy represents an exciting advancement in wound care space that holds a number of clinical applications.
  • Similarly, immobility for long periods can lead to pressure ulcers, the treatment of which might need the use of NPWT devices.
  • This segment currently accounts for a 28.4% share of the global Negative Pressure Wound Therapy (NPWT) market.

2021 Negative Pressure Wound Therapy Devices - Medical Devices Pipeline Product Landscape Report - ResearchAndMarkets.com

Retrieved on: 
Friday, February 4, 2022

The "Negative Pressure Wound Therapy (NPWT) Devices - Medical Devices Pipeline Product Landscape, 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Negative Pressure Wound Therapy (NPWT) Devices - Medical Devices Pipeline Product Landscape, 2021" report has been added to ResearchAndMarkets.com's offering.
  • This report provides comprehensive information about the Negative Pressure Wound Therapy (NPWT) Devices pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
  • Negative Pressure Wound Therapy (NPWT) is used to treat acute and chronic wounds.
  • A vacuum source of NPWT Device creates continuous or intermittent negative pressure inside the wound to remove fluid, exudates, and infectious materials to which helps in healing and closure.

InfuSystem to Report Second Quarter 2021 Financial Results on Thursday, August 12, 2021

Retrieved on: 
Thursday, August 5, 2021

ROCHESTER HILLS, Michigan, Aug. 05, 2021 (GLOBE NEWSWIRE) -- InfuSystem Holdings, Inc. (NYSE American: INFU), (InfuSystem or the Company), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today announced that it will issue second quarter 2021 financial results on Thursday, August 12, 2021, before the market opens.

Key Points: 
  • ROCHESTER HILLS, Michigan, Aug. 05, 2021 (GLOBE NEWSWIRE) -- InfuSystem Holdings, Inc. (NYSE American: INFU), (InfuSystem or the Company), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today announced that it will issue second quarter 2021 financial results on Thursday, August 12, 2021, before the market opens.
  • The Company will also conduct a conference call for all interested investors on Thursday, August 12, 2021, at 9:00 a.m. Eastern Time to discuss its financial results.
  • InfuSystem Holdings, Inc. (NYSE American: INFU), is a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers.
  • The second platform, Durable Medical Equipment Services (DME Services), supports the ITS platform and leverages strong service orientation to win incremental business from its direct payer clients.

Insights on the Negative Pressure Wound Therapy Global Market to 2026 - Featuring Alkermes, Abbvie and AstraZeneca Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 1, 2021

This situation put tremendous pressure on hospitals and other healthcare centers to provide services to COVID-19 patients.?

Key Points: 
  • This situation put tremendous pressure on hospitals and other healthcare centers to provide services to COVID-19 patients.?
  • As per the article published in The Wounds Clinic, 2020, the COVID-19 pandemic has changed the perspectives on the way wound clinics have been operating.
  • Therefore, owing to the aforementioned factors, North America is expected to have a significant share of the market studied.
  • Hence the rising aging population will increase the demand for negative pressure wound therapy.

Guard Medical Announces the Enrollment of the First 5 Patients in the Post-market Study of Its NPseal

Retrieved on: 
Monday, June 7, 2021

Privately-held company Guard Medical Inc. today announces enrollment of the first five patients in the post-market study of its NPsealTM at Keck Medical Center of USC.

Key Points: 
  • Privately-held company Guard Medical Inc. today announces enrollment of the first five patients in the post-market study of its NPsealTM at Keck Medical Center of USC.
  • NPsealTM is the next generation, All-in-One Negative Pressure Wound Therapy (NPWT) system for the treatment of closed surgical incisions.
  • Guard Medicals simple, innovative and cost-effective NPWT NPsealTM is a wearable dressing with an integrated pump that establishes and maintains negative pressure with just a few pinches.
  • The first cases demonstrate fast application and easy activation of the NPsealTM, stated Machiel van der Leest, CEO of Guard Medical.

$892 Million Single-Use Negative Pressure Wound Therapy Devices Global Market to 2028 - by Wound Type, End-use and Geography - ResearchAndMarkets.com

Retrieved on: 
Friday, June 4, 2021

The "Single-Use Negative Pressure Wound Therapy Devices Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Wound Type and End Use, and Geography" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Single-Use Negative Pressure Wound Therapy Devices Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Wound Type and End Use, and Geography" report has been added to ResearchAndMarkets.com's offering.
  • The global single-use negative pressure wound therapy devices market is expected to reach US$ 892.32 million by 2028 from US$ 462.05 million in 2020.
  • Wound therapy devices such as negative pressure wound therapy devices and wound irrigation devices are gaining popularity among healthcare service providers.
  • Thus, rise in number of cases of burns and related injuries is driving the single-use negative pressure wound therapy devices market.

Guard Medical Announces FDA 510k Clearance for Increased Wear Time of Its Novel NPseal, the First All-in-one NPWT Surgical Dressing

Retrieved on: 
Monday, May 24, 2021

Privately-held company Guard Medical Inc. today announces FDA 510k clearance of a wear time extension from 3 to 6 days for its next generation Negative Pressure Wound Therapy (NPWT) dressing NPsealTM for the treatment of closed surgical incisions.

Key Points: 
  • Privately-held company Guard Medical Inc. today announces FDA 510k clearance of a wear time extension from 3 to 6 days for its next generation Negative Pressure Wound Therapy (NPWT) dressing NPsealTM for the treatment of closed surgical incisions.
  • Guard Medicals simple, innovative and cost-effective NPWT NPsealTM is a wearable dressing with an integrated pump that establishes and maintains negative pressure with just a few pinches.
  • In a go-to-market study commissioned by Guard Medical, Fletcher Spaght Inc. encountered high receptiveness amongst surgeons of the NPsealTM but observed that surgeons would prefer a longer wear time.
  • NPseals ease-of-use and cost effectiveness makes, for the first time, prophylactic use of NPWT for all eligible closed surgical wounds possible.

Net Health Adds Smith+Nephew's RENASYS GO Negative Pressure Wound Therapy System to Net Health® Wound Care Connections Lineup

Retrieved on: 
Tuesday, March 9, 2021

Net Health is a leading provider of cloud-based software that serves specialty medical providers across the continuum of care, including wound care practitioners.Net Health Wound Care is used by 20,000 providers daily to drive specialized wound care workflow and documentation compliance assurance.

Key Points: 
  • Net Health is a leading provider of cloud-based software that serves specialty medical providers across the continuum of care, including wound care practitioners.Net Health Wound Care is used by 20,000 providers daily to drive specialized wound care workflow and documentation compliance assurance.
  • Smith+Nephew's widely used RENASYS GO system will be available to wound care clinics through Net Health's Net Health Wound Care Connections portal, a proprietary ordering system for clients.
  • The addition of RENASYS GO System gives Net Health's clients access to one of the industry's most advanced at-home wound management solutions.
  • "Negative Pressure Wound Therapy Market Global Market Analysis, Insights and Forecast, 2019-2026,"
    View original content to download multimedia: http://www.prnewswire.com/news-releases/net-health-adds-smithnephews-ren...